Please try another search
For the fiscal year ended 31 December 2007, GenexPharmaceutical, Inc. revenues increased 33% to $3.2M. Netincome decreased 45% to $343K. Revenues reflect an increasein demand for the Company's products and services due tofavorable market conditions. Net income was offset bySelling Expense increase of 53% to $1M (expense), Research& Development increase from $1K to $196K (expense).
Period Ending: | Dec 31, 2007 | Sep 30, 2007 | Jun 30, 2007 | Mar 31, 2007 |
---|---|---|---|---|
Total Revenue | 0.9 | 0.86 | 0.75 | 0.73 |
Gross Profit | 0.81 | 0.79 | 0.65 | 0.63 |
Operating Income | -0.08 | 0.08 | 0.2 | 0.26 |
Net Income | -0.07 | 0.06 | 0.16 | 0.2 |
Period Ending: | Dec 31, 2007 | Sep 30, 2007 | Jun 30, 2007 | Mar 31, 2007 |
---|---|---|---|---|
Total Assets | 8.65 | 7.84 | 7.28 | 6.59 |
Total Liabilities | 3.91 | 3.03 | 2.74 | 2.28 |
Total Equity | 4.74 | 4.81 | 4.54 | 4.31 |
Period Ending: | Dec 31, 2007 | Sep 30, 2007 | Jun 30, 2007 | Mar 31, 2007 |
---|---|---|---|---|
Period Length: | 12 Months | 9 Months | 6 Months | 3 Months |
Cash From Operating Activities | 0.53 | 0.52 | 0.32 | 0.13 |
Cash From Investing Activities | -1.88 | 0 | -0 | -0 |
Cash From Financing Activities | 1.57 | -0.28 | -0.05 | -0.24 |
Net Change in Cash | 0.24 | 0.27 | 0.28 | -0.11 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review